February 25, 2026   |   Read Online Last Look Before the Bell: See Why (INBS) is Lighting Up Our Radar Right Now Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Daily Edge Report Puts (INBS) At The Top Of Today's Watchlist—Wednesday, February 25, 2026 Don't miss the next breakout — get real-time alerts sent straight to your phone! Pull Up (INBS) While It's Still Early… February 25, 2026 Last Look Before the Bell | See Why (INBS) is Lighting Up Our Radar Right Now Dear Reader, Most systems people rely on every day were built decades ago, and many of them haven't changed much since. Screening is one of them. It's often slow. Invasive. Time-consuming for both the person being tested and the organization running it. But that process is starting to shift. Across workplaces, safety-sensitive industries, and compliance-driven environments, there's growing demand for faster, simpler ways to get answers, without disrupting operations or putting people through outdated procedures. That's where a new approach is beginning to take hold. And one company working within that shift is Intelligent Bio Solutions Inc. (Nasdaq: INBS). (INBS) is developing a non-invasive screening system that uses a fingerprint, not traditional collection methods, to deliver results in minutes. But the story isn't just about technology. (INBS)'s current setup adds another layer. Following a recent reverse split, the public float remains limited, with around 1.5M shares listed as available to the public. When companies have small floats like this, the potential exists for big swings if demand begins to shift. Coverage is also beginning to take shape. An analyst report from Ladenburg Thalmann maintains a $12.00 target, suggesting a 200% upside potential from recent levels. At the same time, (INBS) continues to build its commercial presence. And that's just a few of the reasons why (INBS) is topping our watchlist this morning—Wednesday, February 25, 2026. Modernizing Screening with Fingerprint Technology Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company focused on transforming how screening is performed by replacing traditional methods with a faster, non-invasive approach. At the core of its platform is the Intelligent Fingerprinting Dr-ug Screening System — a portable solution that uses a simple fingerprint to detect substances through trace amounts of sweat. Results can be delivered in minutes without the need for conventional collection methods or specialized facilities. The system is designed to be: Non-invasive and easy to use Rapid, with results in under 10 minutes Portable, allowing for on-site testing Efficient, reducing operational disruption The platform is built around two main components: Single-use cartridges that collect and analyze fingerprint sweat samples A portable reader device that processes results on-site within minutes In addition, the company offers the SmarTest® Patch, a wearable solution designed for continuous monitoring over several days, expanding use beyond point-in-time screening. Together, these products create a system focused on fast, non-invasive, and on-site testing, with applications across workplace and compliance-driven environments. Scalable Platform with Recurring Use Potential Beyond the initial hardware deployment, the platform is designed around a recurring usage model. Each test requires a single-use cartridge, meaning that as more devices are installed and used, ongoing demand for consumables can increase alongside adoption. As (INBS) continues to expand its installed base of readers, management has highlighted that this growth can support sustained cartridge demand over time, creating a model tied to repeat utilization rather than one-time sales. This "device + consumable" structure is often described as a razor-and-blade model, where the initial system deployment is followed by recurring usage tied to everyday operations. At the same time, the underlying fingerprint-based technology is not limited to its current screening applications. The platform is designed for rapid, non-invasive, point-of-care testing, with the potential to expand into broader diagnostic and health-related use cases as development progresses. (INBS) is also advancing through key regulatory pathways, including ongoing clinical studies to support a U.S. FDA 510(k) submission, which represents a critical step toward entering the U.S. market, one of the largest screening markets globally. Together, the combination of recurring consumables, expanding applications, and regulatory progress highlights a platform built to scale as adoption increases across new markets and use cases. Market Landscape: Workplace Screening Demand Workplace safety and compliance remain a growing focus across industries, particularly in environments where impairment can impact operations and employee well-being. An estimated 17.8% of U.S. adults (45.7M people) report recent illicit dr-ug use, with approximately 8.6% of full-time workers also reporting use. Over 70% of employers say they have been affected by prescription dr-ug misuse.  This backdrop supports a global dr-ug screening market projected to reach approximately $14–15B by 2030, driven by increasing regulation, workplace safety standards, and demand for faster, on-site solutions. (INBS)'s platform is already deployed across industries including construction, manufacturing, transportation, healthcare, and law enforcement, supporting organizations that collectively represent over 1.4M employees.  As companies continue to prioritize real-time screening, efficiency, and minimal disruption, demand for faster, non-invasive testing solutions is expected to grow. Building Momentum Behind the Scenes Recent updates highlight continued progress across capital, operations, and expansion initiatives as the company positions for broader commercialization. Capital Raise to Support Growth: In January 2026, (INBS) announced the closing of a $10M private placement, providing additional capital to support operations, scaling efforts, and ongoing development initiatives. Expanded Manufacturing Capacity & Margin Potential: A new strategic partnership with Syrma Johari MedTech is expected to significantly enhance production capabilities. The collaboration is projected to deliver over 40% cost savings, improve gross margins by approximately 20 percentage points, and expand manufacturing capacity to roughly 4x current levels. Supply Chain & Global Scaling Infrastructure: The manufacturing partnership also strengthens supply-chain resilience, adds geographic diversification, and supports (INBS)'s ability to scale production as demand increases across international markets. Commercial Expansion and Customer Growth: (INBS) continues to expand its commercial footprint, including adding new customer accounts across multiple industries, with adoption increasing in sectors such as transportation, construction, and government.  Together, these developments point to a company actively building out infrastructure, capital resources, and commercial reach,  key elements that can support continued growth as adoption expands. 7 Reasons Why (INBS) Is Topping Our Watchlist This Morning — Wednesday, February 25, 2026 1. Positioned in a Growing Segment of Diagnostic Technology: (INBS) operates within the diagnostic and screening space, where demand continues to increase for faster, on-site, and non-invasive solutions. 2. Non-Invasive, Rapid Screening Platform: Its fingerprint-based system is designed to deliver results in minutes, removing the need for traditional collection methods and specialized facilities. 3. Tightly Structured Share Float: Following a recent reverse split, the company maintains a limited public float of around 1.5M shares available, a structure that can amplify movement as activity shifts. 4. Analyst Coverage: Published coverage includes a $12.00 target,  suggesting 200% upside potential from recent levels. 5. Record Revenue and Continued Growth: Recent financial updates highlight record quarterly revenue and a third consecutive quarter of growth, indicating expanding commercial traction. 6. Recurring Revenue Model Building: Consumable testing cartridges now represent a growing portion of total revenue, supporting ongoing usage as the installed base expands. 7. Expanding Global Footprint: The platform is now deployed across hundreds of customers in more than 25 countries, with a growing number of testing units in the field. Pull Up (INBS) While It's Still Early… When you step back and look at the full picture, (INBS) is starting to show a combination of factors that tend to draw early attention. The share structure remains tight following a recent reverse split, with an estimated float of around 1.5M shares, a setup where even modest shifts in activity can become more noticeable. At the same time, the business is showing continued progress, 48% year-over-year revenue growth, with H1 FY2026 revenue surpassing $2M. Add in ongoing commercial rollout, growing adoption across international markets, and continued progress toward broader market access…  (INBS) is operating within a segment focused on faster, on-site, non-invasive screening, where demand continues to evolve. That's why (INBS) is on our screen this morning. Take a closer look at (INBS) while it's still early. And keep an eye out — the next update could be hitting within the next 60–90 minutes. Sincerely, Joel Locke Senior Editor The Daily Edge Report DailyEdgeReport.com ("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a single member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 02/25/2026 and ending on 02/25/2026 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, GG Media Holdings LLC has been paid thirteen thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://dailyedgereport.com/disclosure/inbs-Qe5HO/#details   Update your email preferences or unsubscribe here © 2026 Daily Edge Report 1401 Pennsylvania Ave Suite 105 Wilmington, Delaware 19806, United States Terms of Service